title: Efficacy and safety of single-dose systemic methotrexate in the treatment of ectopic pregnancy.
abstract: OBJECTIVE
  To evaluate the safety and efficacy of single-dose systemic methotrexate (MTX) in the treatment of ectopic pregnancy (EP).
  
  
  METHODS
  A database was started and continued prospectively for 35 patients meeting criteria for MTX therapy from June 1991 to October 1993. Follow-up was performed retrospectively on all patients with EPs (n = 82) by evaluating hospital and clinic records and by contacting affiliated physicians and individual patients.
  
  
  METHODS
  The University of Vermont Reproductive Endocrinology Service.
  
  
  METHODS
  Methotrexate 50 mg/m2 was administered IM; blood samples were collected on days 0, 4, and 7 of MTX therapy and weekly thereafter until hCG titers became < 4 mIU/mL.
  
  
  RESULTS
  Thirty-five of 82 (42.7%) patients diagnosed with EP were treated with MTX. The mean hCG concentration on day of treatment was 1388.1 +/- 463.5 (+/- SE) mIU/mL, and mean time to complete resolution of hCG was 23.1 +/- 2.9 days. Thirty of 35 (85.7%) were successfully treated with a single dose of MTX. Five of 35 (14.3%) failed therapy and required laparoscopic surgery. Twelve of 35 (34.3%) experienced mild side effects that resolved spontaneously. Ten of 13 (76.9%) demonstrated tubal patency at follow-up hysterosalpingogram. Of the 15 patients seeking pregnancy, 3 of 15 (20.0%) conceived, resulting in 3 term deliveries and 2 spontaneous abortions.
  
  
  CONCLUSIONS
  Our results support the use of single-dose systemic MTX for the treatment of unruptured EP in carefully selected patients.
authors.affiliation: Department of Obstetrics and Gynecology, University of Vermont College of Medicine, Burlington 05405.
authors.forename: J L
authors.initials: JL
authors.lastname: Glock
authors.forename: J V
authors.initials: JV
authors.lastname: Johnson
authors.forename: J R
authors.initials: JR
authors.lastname: Brumsted
mesh_terms: D000293:Adolescent; D000328:Adult; D006063:Chorionic Gonadotropin / Q000097:blood; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D010535:Laparoscopy; D008727:Methotrexate / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D017699:Pelvic Pain / Q000209:etiology; D011247:Pregnancy; D011256:Pregnancy Outcome; D011271:Pregnancy, Ectopic / Q000150:complications / Q000188:drug therapy* / Q000601:surgery; D011446:Prospective Studies; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D006063:Chorionic Gonadotropin; D008727:Methotrexate